On July 27, 2026 DifGen Pharmaceuticals LLC reported that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application and issued a "study may proceed" letter for DFGN-101, an intramuscular injection under development for the treatment of advanced or metastatic breast cancer in women.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DFGN-101 is designed to be administered as a single intramuscular injection, compared with the two separate injections required for the currently marketed reference product. If approved, the product would reduce the number of injections a patient receives at each treatment visit.

Under the agreed development pathway, DifGen will proceed with preclinical toxicology studies in rat and rabbit and a Phase 1 pharmacokinetic study. A clinical endpoint/efficacy study is not required. The Agency’s position was supported by the company’s Chemistry, Manufacturing and Controls (CMC) data package and by results from a pilot pharmacokinetic study showing a PK profile comparable to that of the reference product.

The clearance reflects DifGen’s formulation and clinical development capabilities and its focus on identifying efficient development pathways for technically complex programs.

(Press release, DifGen Pharmaceuticals, JUL 27, 2026, View Source [SID1234669442])